Biogen Inc. Q1 2026 Earnings Call Summary
Biogen Inc. reported a 12% growth in new products for Q1 2026, driven by strategic reinvestment and reallocation of commercial resources. The company highlighted the proposed acquisition of Apellis as a strategic move into ophthalmology and nephrology, with expectations of EPS accretion in 2027. Management also noted the importance of the LEQEMBI subcutaneous induction PDUFA date as a key catalyst.
Topics: Apellis Acquisition Biogen Inc. LEQEMBI PDUFA Date Q1 2026 Earnings Strategic Transformation